Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.61 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839568 | 0.96 | KLK7 (0.62) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL630096 | 0.88 | FKBP1A (0.71) | FKBP1AKLK7KLK5PREPNPSR1 | |
| SCHEMBL3578099 | 0.88 | FKBP1A (0.71) | FKBP1AKLK7KLK5PREPNPSR1 | |
| SCHEMBL27881364 | 0.87 | PREP (0.60) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL630241 | 0.87 | PREP (0.62) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL82714 | 0.87 | PREP (0.62) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL630208 | 0.87 | PREP (0.62) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL16272917 | 0.87 | FKBP1A (0.66) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL7326760 | 0.87 | FKBP1A (0.66) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL8280028 | 0.86 | FKBP1A (0.66) | FKBP1AKLK7KLK5PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | FKBP1A 1084/4885KLK7 1123/4885KLK5 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.